About Aegerion Pharmaceuticals (NASDAQ:AEGR)
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:AEGR
CUSIP00767E10
Phone+1-617-5007867
Debt
Debt-to-Equity Ratio-19.22%
Current Ratio1.02%
Quick Ratio0.67%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-75.07%
Return on EquityN/A
Return on Assets-29.21%
Miscellaneous
Employees318
Outstanding Shares29,540,000
Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions
What is Aegerion Pharmaceuticals' stock symbol?
Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."
How were Aegerion Pharmaceuticals' earnings last quarter?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) released its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $43 million. The firm's revenue for the quarter was down 39.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.
Has Aegerion Pharmaceuticals been receiving favorable news coverage?
Media coverage about AEGR stock has been trending positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a news impact score of 0.46 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Aegerion Pharmaceuticals?
Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aegerion Pharmaceuticals' stock price today?
One share of AEGR stock can currently be purchased for approximately $1.97.
How big of a company is Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe.
How can I contact Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.
MarketBeat Community Rating for Aegerion Pharmaceuticals (AEGR)
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aegerion Pharmaceuticals (NASDAQ:AEGR) Earnings History and Estimates Chart
Aegerion Pharmaceuticals (NASDAQ AEGR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/3/2016 | Q3 2016 | ($0.67) | ($0.46) | $27.00 million | $35.39 million | View | N/A |  |
| 8/9/2016 | Q2 2016 | ($0.25) | ($0.87) | | $44.53 million | View | N/A | |
| 5/16/2016 | Q1 | ($0.58) | ($1.72) | $43.00 million | $35.70 million | View | Listen | |
| 2/25/2016 | Q4 | ($0.89) | ($0.69) | $47.74 million | $49.00 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.42) | ($0.34) | $59.72 million | $67.30 million | View | N/A | |
| 8/5/2015 | Q2 | ($0.27) | ($0.01) | $58.98 million | $64.20 million | View | N/A | |
| 5/4/2015 | Q1 2015 | ($0.27) | ($0.19) | $50.42 million | $59.38 million | View | N/A | |
| 2/26/2015 | Q4 2014 | $0.05 | ($0.12) | $49.20 million | $51.71 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.18) | ($0.12) | $48.60 million | $43.70 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.41) | ($0.33) | $35.40 million | $36.00 million | View | Listen | |
| 5/6/2014 | Q1 | ($0.35) | ($0.54) | $33.58 million | $27.00 million | View | Listen | |
| 2/26/2014 | Q413 | ($0.30) | ($0.14) | $24.51 million | $24.50 million | View | Listen | |
| 10/29/2013 | Q313 | ($0.50) | ($0.43) | $13.07 million | $16.30 million | View | N/A | |
| 7/30/2013 | Q2 2013 | ($0.62) | ($0.66) | $4.27 million | $6.50 million | View | N/A | |
| 4/30/2013 | Q1 2013 | ($0.72) | ($0.64) | $1.07 million | $1.23 million | View | N/A | |
| 3/6/2013 | Q4 2012 | ($0.62) | ($0.86) | | | View | N/A | |
| 11/7/2012 | Q312 | ($0.56) | ($0.59) | | | View | N/A | |
| 8/8/2012 | Q2 2012 | ($0.54) | ($0.60) | | | View | N/A | |
| 5/1/2012 | Q1 2012 | ($0.59) | ($0.51) | | | View | N/A | |
| 3/6/2012 | Q4 2011 | ($0.54) | ($0.61) | | | View | N/A | |
| 10/27/2011 | Q3 2011 | ($0.45) | ($0.48) | | | View | N/A | |
| 7/27/2011 | Q2 2011 | ($0.40) | ($0.49) | | | View | N/A | |
| 4/28/2011 | Q1 2011 | ($0.42) | ($0.39) | | | View | N/A | |
| 3/2/2011 | Q4 2010 | ($0.34) | ($0.92) | | | View | N/A | |
| 11/30/2010 | Q3 2010 | | ($3.61) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Aegerion Pharmaceuticals (NASDAQ:AEGR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aegerion Pharmaceuticals (NASDAQ AEGR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Aegerion Pharmaceuticals (NASDAQ AEGR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/13/2016 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 75,000 | $1.75 | $131,250.00 | | |
| 9/12/2016 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 276,000 | $1.66 | $458,160.00 | | |
| 8/19/2014 | Mark J Fitzpatrick | CFO | Buy | 1,150 | $30.64 | $35,236.00 | | |
| 7/31/2014 | Marc D Beer | CEO | Buy | 10,000 | $33.65 | $336,500.00 | | |
| 6/3/2014 | Marc D Beer | CEO | Buy | 10,000 | $30.12 | $301,200.00 | | |
| 5/27/2014 | Marc D Beer | CEO | Buy | 10,000 | $31.59 | $315,900.00 | | |
| 5/20/2014 | Marc Beer | CEO | Buy | 10,000 | $30.53 | $305,300.00 | 43,000 | |
| 5/8/2014 | Anne Vanlent | Director | Buy | 4,000 | $33.78 | $135,120.00 | 4,000 | |
| 5/8/2014 | Marc Beer | CEO | Buy | 30,000 | $35.31 | $1,059,300.00 | 33,000 | |
| 4/30/2014 | Craig Fraser | Insider | Sell | 2,250 | $43.55 | $97,987.50 | | |
| 3/31/2014 | Craig Fraser | Insider | Sell | 2,250 | $46.20 | $103,950.00 | | |
| 3/14/2014 | Mark Sumeray | Insider | Sell | 2,000 | $51.34 | $102,680.00 | | |
| 2/11/2014 | Craig Fraser | Insider | Sell | 2,250 | $67.00 | $150,750.00 | | |
| 12/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $66.34 | $132,680.00 | | |
| 10/30/2013 | Marc D Beer | CEO | Sell | 40,000 | $87.79 | $3,511,600.00 | | |
| 10/29/2013 | Sandford D Smith | Director | Sell | 2,502 | $95.00 | $237,690.00 | | |
| 10/15/2013 | Mark Sumeray | Insider | Sell | 2,000 | $80.33 | $160,660.00 | | |
| 10/7/2013 | Mark Sumeray | Insider | Sell | 3,500 | $93.17 | $326,095.00 | | |
| 9/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $89.77 | $179,540.00 | | |
| 9/5/2013 | Perceptive Advisors Llc | Major Shareholder | Sell | 750,000 | $89.20 | $66,900,000.00 | | |
| 8/21/2013 | David Scheer | Director | Sell | 20,000 | $84.58 | $1,691,600.00 | 10,000 | |
| 8/16/2013 | Mark Sumeray | Insider | Sell | 2,000 | $88.71 | $177,420.00 | | |
| 8/15/2013 | Marc Beer | CEO | Sell | 60,000 | $88.54 | $5,312,400.00 | 199,061 | |
| 8/14/2013 | Mark Fitzpatrick | CFO | Sell | 7,500 | $93.44 | $700,800.00 | 500 | |
| 8/12/2013 | Sandford Smith | Director | Sell | 10,000 | $92.32 | $923,200.00 | | |
| 7/15/2013 | Mark Sumeray | Insider | Sell | 2,000 | $78.77 | $157,540.00 | | |
| 6/17/2013 | Mark Sumeray | Insider | Sell | 6,000 | $65.27 | $391,620.00 | | |
| 5/15/2013 | Mark Sumeray | Insider | Sell | 6,000 | $47.32 | $283,920.00 | | |
| 2/1/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $27.79 | $1,389,500.00 | | |
| 1/18/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $27.62 | $1,381,000.00 | | |
| 1/17/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $26.73 | $1,336,500.00 | | |
| 1/11/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 475,000 | $27.07 | $12,858,250.00 | | |
| 12/4/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 20,000 | $21.27 | $425,400.00 | | |
| 11/29/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 30,000 | $22.71 | $681,300.00 | | |
| 11/28/2012 | Perceptive Advisors Llc | Major Shareholder | Buy | 150,000 | $21.25 | $3,187,500.00 | | |
(Data available from 1/1/2013 forward)
Aegerion Pharmaceuticals (NASDAQ AEGR) News Headlines
| Source: |
|
Aegerion Pharmaceuticals (NASDAQ:AEGR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aegerion Pharmaceuticals (NASDAQ:AEGR) Income Statement, Balance Sheet and Cash Flow Statement
Aegerion Pharmaceuticals (NASDAQ AEGR) Stock Chart for Thursday, April, 26, 2018
Loading chart…
